425 related articles for article (PubMed ID: 19109822)
1. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors in cancer therapy.
Orlowski RZ
Methods Mol Biol; 2005; 301():339-50. PubMed ID: 15917644
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Mitsiades CS
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition as a novel therapeutic target in human cancer.
Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition in multiple myeloma.
Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
Groll M; Berkers CR; Ploegh HL; Ovaa H
Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
[TBL] [Abstract][Full Text] [Related]
13. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
14. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
15. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Dick LR; Fleming PE
Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
[TBL] [Abstract][Full Text] [Related]
16. [Proteasome inhibitors].
Saeki Y; Fukunaga K; Tanaka K
Nihon Rinsho; 2010 Oct; 68(10):1818-22. PubMed ID: 20954323
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors in lung cancer.
Scagliotti G
Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors: poisons and remedies.
Meiners S; Ludwig A; Stangl V; Stangl K
Med Res Rev; 2008 Mar; 28(2):309-27. PubMed ID: 17880010
[TBL] [Abstract][Full Text] [Related]
20. [Proteasome inhibitors for multiple myeloma].
Yano H; Iida S
Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
[No Abstract] [Full Text] [Related]
[Next] [New Search]